COMPANY HISTORY
RenaSci was founded in 2001 by three senior executives from the pharmaceutical
industry. The Directors and Senior Management have proven drug discovery track
records, having held leadership positions in teams that put ten clinical candidates
into development. They also played key roles in obtaining approval for the anti-obesity
drug, sibutramine (Meridia®, Reductil®) and the atypical antipsychotic, zotepine
(Zoleptil®). These combined skills and expertise enable RenaSci to offer high
quality consultancy and experimental services for programs in obesity, diabetes
and other metabolic disorders, psychiatry (including depression, anxiety, schizophrenia,
drug abuse) and neurology (including epilepsy, Parkinson's disease, stroke and
other neurodegenerative disorders). RenaSci has no in-house drug discovery projects
to produce conflicts of interest, and client confidentiality is guaranteed.
KEY CONTACTS
Helen Rowley, Ph.D.
Head of Microdialysis
+44 (0) 115 912 4230
helen.rowley@renasci.co.uk
Rob Jones, Ph.D., MBA
Head of Business Development
+44 (0) 115 912 4262
rob.jones@renasci.co.uk
CONSULTANCY
Evaluation of licensing opportunities
Strategic reviews of discovery and development portfolios
Participation on scientific advisory boards
Target evaluation and validation
Optimization of lead molecules and drug candidates
Preparation of drug development plans
Differentiation from competitors
Scientific writing and regulatory dossier preparation
Advocate support at regulatory hearings
EXPERIMENTAL
Flexible research programs customized to clients’ needs
Agreed timelines with regular client updates
Reports to regulatory standards
Specialist assays using human tissues
Techniques applicable from target validation through to post-marketing support
Experienced pharmaceutical industry-trained research staff
State-of the-art laboratories and equipment
OBESITY AND METABOLIC DISORDERS
Specific models of genetic and dietary-induced obesity
Acute and chronic food intake
Satiety profiling and microstructural analysis of feeding
Basal metabolic rate by indirect calorimetry
Fecal fat analysis Energy balance determination
Body composition analysis
Non-invasive body fat determination (TOBEC)
Plasma indices of glycemic control, lipids and leptin
Mitochondrial respiration/membrane potential/ion flux
Perfused pancreatic islet preparations (including human)
Lipolysis in isolated adipocytes (including human)
Oxygen consumption in cell lines
CNS - PSYCHIATRY AND NEUROLOGY
Models for evaluating drug candidates in psychiatry and neurology
Models of cognition and attention
Abuse liability testing including drug discrimination
Neurotoxic lesion models
Central administration including rapid non-surgical technique
Continuous drug infusion (centrally or peripherally)
Epilepsy models using hippocampal slices and organotypic cultures
Neuronal cell death and neuroprotection
Morphological assessment of synaptic and neuronal network viability
In vivo microdialysis of neurotransmitters
